Cancer Immunotherapy: Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy (Adv. Mater. 34/2019)
Source abstract
Abstract
The two different pathways to activate host immature dendritic cells (DCs) into mature antigen-presenting DCs for cancer immunotherapy using mesoporous silica nanoparticles (MSNs) and mesoporous silica microrods (MSRs) are discussed by Jaeyun Kim and co-workers in article number 1803953. MSNs deliver immunomodulators into immature DCs by phagocytosis to active them, while the macroporous scaffold composed of randomly stacked MSRs recruits immature DCs and activates them in artificial microenvironments generated by the scaffold itself.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemical Engineering Sungkyunkwan University (SKKU) Suwon 16419 Republic of Korea
Samsung Advanced Institute for Health Sciences & Technology (SAIHST) Sungkyunkwan University (SKKU) Suwon 16419 Republic of Korea
Biomedical Institute for Convergence at SKKU (BICS) Sungkyunkwan University (SKKU) Suwon 16419 Republic of Korea
References
Reference metadata was not supplied for this record.